18F-FDG PET/CT IN THE EARLY DIAGNOSIS OF CARDIOTOXICITY: EVALUATION OF THE BEST SITE TO OBTAIN THE CARDIAC SUV INDEX
Cardiotoxicity. PET/CT. Myocardial uptake. Cardiac sites. Reproducibility
The diagnosis of cardiotoxicity has been a challenge in the daily routine of the oncologist. Today's diagnostic methods are not capable of detecting this clinical condition early enough. In this context, studies indicate that 18F-FDG PET/CT is a complementary test that can identify cardiotoxicity earlier. In this way, cardioprotection measures can be started earlier, improving the chances of increasing patient survival. Objective: To evaluate the behavior of the standardized uptake value (SUV) of the radiopharmaceutical 18F-FDG before, during and after chemotherapy (QT) at different cardiac sites, as well as to measure the degree of reproducibility for the method in the context of cancer treatment follow-up. Materials and Methods: Retrospective cohort including lymphoma patients who underwent 18F-FDG PET/CT before, during and/or after chemotherapy. The uptake behavior through the mean and maximum SUVs was evaluated in four cardiac sites and in control sites in the aorta and liver. Twenty exams were randomized for reproducibility analysis by two examiners who were blinded to each other's results. Each one of them did the evaluation in a second moment to elucidate the intra-observer reproducibility. Results: A significant increase in SUVs was observed in all cardiac sites in the interim and final moments (post-terminus of QT) when compared with pre-QT SUVs. The left ventricular (LV) free wall was the cardiac region with the greatest increase in 18F-FDG uptake. As for the reproducibility, it was possible to verify substantial results for the reliability of the measurement of SUVs, both intra and inter-observer. Conclusions: Cardiac uptake of 18F-FDG increased along QT, with the LV free wall being the site with the greatest increase. The reproducibility analysis showed high intra- and inter-observer correlation values.